Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
MOLNZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of first patient imaging and dosimetry data of MP0712, its DLL3-targeted Radio-DARPin candidate co-developed with strategic partner Orano Med, at the 8th Theranostics World Congress (TWC), taking place in Cape Town, South Africa on January 29-February 1.
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
MOLNZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update on its latest progress, developments plans and expected 2026 milestones, which it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
MOLNZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), has today announced it will present updated data from a Phase 1/2a trial of the multispecific T-cell engager MP0533 in patients with acute myeloid leukemia (AML) in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.
Prism and Molina Healthcare of Illinois Partner to Launch Statewide “Ready by 10/15” Back‑to‑School Health Records Check Hotline and Mobile Clinics
MOLNCHICAGO--(BUSINESS WIRE)--Prism and Molina Healthcare of Illinois partner to launch statewide “Ready by 10/15” back‑to‑school health records check hotline and mobile clinics.
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
MOLNZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the first half of 2025.
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
MOLNZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company’s Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies.
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
MOLN– Live video webcast on Wednesday, August 20th at 2:00 PM ET
Molina Healthcare of Illinois Invests $1.6 Million to Improve Access to Health Care
MOLNCHICAGO--(BUSINESS WIRE)--Molina Healthcare of Illinois invests $1.6 million to improve access to health care.
Molecular Partners Presents Data From Ongoing Phase 1/2a Trial Of MP0533 In AML At EHA 2025; Three Of Eight Evaluable Patients With R/r AML Responded After Cycle 1 In Ongoing Cohort 8; Data Support Further Dose Optimization To Maximize Therapeutic Benefit
MOLNMolecular Partners To Cut Up To 40 Jobs In Strategic Review, Extends Cash Runway Into 2028
MOLNCORRECTION: Molecular Partners Q1 EPS $(0.51)
MOLNMolecular Partners Q1 EPS $0.51
MOLNMolecular Partners Presents New Preclinical Data On Radio-DARPin And Switch-DARPin Programs At AACR 2025; First Preclinical Data Of Novel Targeted Radio-DARPin Against Mesothelin, In Co-Development With Orano Med
MOLNLifeSci Capital Initiates Coverage On Molecular Partners with Outperform Rating, Announces Price Target of $12
MOLNMolecular Partners FY EPS $(1.81) Up From $(2.13) YoY, Sales $5.65M Down From $7.89M YoY
MOLNMolecular Partners, Orano Med Expand Partnership To Develop Targeted Alpha Radio-Therapies For Cancer
MOLNFor The FY24, At Constant Exchange Rates, Molecular Partners Reiterates Its Guidance For Total Expenses Of CHF 65–70 Million. ~CHF 7 Million Of This Will Be Non-Cash Effective Costs For Share-Based Payments, Pension Accounting And Depreciation. This Guida
MOLNMolecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
MOLNMolecular Partners Expects To Be Funded Into 2026 With Cash And Short-Term Deposits Of CHF 174.1M; Expects Total Operating Expenses Of CHF 70-80 Million For 2024
MOLNWhy Molecular Partners Shares Are Falling
MOLNMolecular Partners AG (NASDAQ: MOLN) shares are trading lower again Thursday on continued weakness after the company recently said its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep.
